Interestingly, FBDS, a hallmark clinical feature of anti-LGI1 encephalitis, was identified in only 16.1% (14/87) of patients in our cohort, which is notably lower than the 30–50% reported in previous studies (8–10, 12). Here, LGI1 is linked to encephalitis.